PE-22-28
TREK-1 Inhibitor / Spadin Analog
PE-22-28 is a peptide analog of spadin that inhibits TREK-1 potassium channels in the brain. Research suggests TREK-1 inhibition may produce rapid antidepressant effects without the side-effect profile of traditional SSRIs.
The Science
What is PE-22-28?
PE-22-28 is a synthetic analog derived from spadin, a fragment of sortilin. It selectively inhibits the TREK-1 potassium channel, which is highly expressed in mood-related brain regions.
TREK-1 knockout animals display depression-resistant phenotypes, leading researchers to investigate TREK-1 inhibitors as potential rapid-acting antidepressants.
PE-22-28 has been studied in preclinical models with promising effects on mood, neuroplasticity, and BDNF expression—often appearing within days rather than weeks.
Laboratory Observations
Key Observed Effects of PE-22-28
Mood Support
Researched for rapid-acting antidepressant effects.
Neuroplasticity
Supports BDNF expression and neural adaptation.
Targeted Mechanism
Selective for TREK-1 channels in mood circuits.
Investigational Application
Active area of mood and neuroplasticity research.
Mechanism of Action
Mechanism of Action
PE-22-28 inhibits TREK-1 channels to enhance serotonergic signaling and mood regulation.
TREK-1 Inhibition
Selectively blocks TREK-1 potassium channels in mood-related brain regions.
Serotonergic Enhancement
Increases serotonergic neuron excitability through channel modulation.
BDNF Support
Promotes BDNF expression and neuroplasticity in preclinical models.
Research-Only Notice
PE-22-28 is categorized by the FDA as for research-purposes-only. It is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease. The information above summarizes effects observed in laboratory studies to date and is provided strictly for scientific and educational reference.